Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis.

Louise E Lansbury¹, MBBS, PhD
Chamira Rodrigo², MRCP, PhD
Jo Leonardi-Bee³, PhD
Jonathan Nguyen-Van-Tam⁴, DM, FFPH, FRCPath, FRSPH, FRSB
Wei Shen Lim⁵, DM, FRCP

Author affiliations:
¹ Research Fellow, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
² Consultant Respiratory Physician, Department of Respiratory Medicine, Nottingham University Hospitals Trust, Nottingham, UK
³ Professor of Medical Statistics and Epidemiology, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
⁴ Professor of Health Protection, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
⁵ Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust and Honorary Professor of Medicine, University of Nottingham, Nottingham, UK

Institution where the work was performed:
University of Nottingham, Nottingham, United Kingdom

Corresponding Author and Address for reprints:
Dr Louise E Lansbury
Department of Epidemiology and Public Health,
Room B104 Clinical Sciences Building,
City Hospital, Nottingham NG5 1PB,
United Kingdom
Louise.Lansbury@nottingham.ac.uk
Telephone: +44 (0)115 8231251

Financial Support:
NIHR Nottingham Biomedical Research Centre, (Nottingham University Hospitals NHS Trust and University of Nottingham), Nottingham, UK

Key words: Influenza, Human; Steroids; Mortality; Meta-analysis

Word Count: Abstract 297; Total 3485

This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2019, Issue 2, DOI: 10.1002/14651858.CD010406. (see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.
Abstract

Objective
Corticosteroids may be beneficial in sepsis but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome.

Data Sources
Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, Web of Science) and trial registries were searched to October 2018 for randomised controlled trials (RCTs), quasi-experimental designs and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza.

Study Selection and Data Extraction
Two researchers independently assessed studies for inclusion. Risk of bias was assessed using the Cochrane Risk of Bias tool (RCTs) or Newcastle-Ottawa Scale (observational studies). Where appropriate, we estimated the effect of corticosteroids by random effects meta-analyses using the generic inverse variance method. Meta-regression analysis was used to assess the association of corticosteroid dose and mortality.

Data Synthesis
We identified 30 eligible studies, all observational apart from one RCT. Twenty-one observational studies were included in the meta-analysis of mortality, which suggested an adverse association with corticosteroid therapy (Odds ratio (OR) 3.90, 95% confidence interval (CI) 2.31 to 6.60, 15 studies; adjusted hazard ratio 1.49, 95% CI 1.09 to 2.02, 6 studies). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted OR 2.74, 95% CI 1.51 to 4.95).
Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly >40 mg methylprednisolone (or equivalent) per day).

Conclusions

Corticosteroid treatment in influenza is associated with increased mortality and hospital-acquired infection, but the evidence relates mainly to high corticosteroid doses and is of low quality with potential confounding by indication a major concern.
Introduction

Induction of proinflammatory cytokines correlates with symptoms and fever in acute influenza (1), with significantly elevated levels in severe influenza (2-4). Endogenous corticosteroids, produced principally by the adrenal glands and regulated by the hypothalamic-pituitary-axis (HPA), possess anti-inflammatory, immunomodulatory and vascular properties (5-7). However, a combination of proinflammatory cytokine inhibition of the HPA, substrate deficiency, damage to the adrenal glands and peripheral corticosteroid resistance could result in adrenal insufficiency during critical illness (8, 9).

Based upon the physiological rationale and evidence from a systematic review incorporating the latest clinical trials (10), a recent ‘Rapid Recommendation’ makes a weak recommendation to give corticosteroids to people with sepsis, with the proviso that it is also reasonable not to prescribe them due to uncertainty of their benefit. The optimal dose of corticosteroids in sepsis remains uncertain (11).

Although moderate quality evidence from randomised controlled trials (RCTs) suggests reduced mortality in severe community-acquired pneumonia (CAP) treated with corticosteroids (12), their role in influenza virus infections has been highly controversial. During the 2009 pandemic, 9% of hospitalised patients and up to 69% of critically-ill intensive care unit (ICU) admissions with influenza received corticosteroids (13-16); subsequent analysis indicated no benefit or even increased mortality with corticosteroid use.

Meta-analysis of ten studies in the original version of this systematic review, suggested that corticosteroid therapy for presumed influenza-associated complications is associated with increased risk of mortality (17). All included studies were observational with confounding by indication a major concern. In light of the ongoing controversy and subsequent publication of additional individual studies, we have updated this systematic review which, together with evaluation of data on the effect of corticosteroid dose on
mortality, aims to summarise the current evidence, highlight important clinical uncertainties and subsequently inform the design of future studies to help definitively address these areas.

Methods

We conducted this updated systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (18) and Meta-Analysis of Observational Studies in Epidemiology guidelines (19). The original study protocol was registered with the Cochrane Database of Systematic Reviews (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010406/abstract).

Study Eligibility

Randomised controlled trials, quasi-experimental designs and observational cohort studies reporting the effect of corticosteroid treatment versus no corticosteroid treatment in people with clinically-diagnosed influenza or influenza-like illness and/or laboratory-confirmed influenza were eligible. The intervention was intravenous or oral corticosteroid of any type, dose or duration, given for any clinical reason but coinciding with influenza confirmed by positive RT-PCR, viral culture or rapid antigen test in respiratory specimens.

The primary outcomes were 30-day mortality and rate of admission to ICUs. Secondary outcomes were 30-day readmission after hospital discharge, the proportion of people requiring mechanical ventilation, length of hospital stay, and adverse events secondary to corticosteroid use, including hospital-acquired infections as defined by individual studies.

Search Methods and Data Extraction

We searched MEDLINE, EMBASE, CINAHL, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from inception to October 2018, and
the following trial registries (October 2018): ISRCTN (http://www.isrctn.com/); World Health Organization International Clinical Trials Registry Platform (http://www.who.int/ictrp); and ClinicalTrials.gov (www.clinicaltrials.gov). The Cochrane Highly Sensitive Search Strategy was used to identify RCTs (20), and the Scottish Intercollegiate Guidelines Network filter to identify observational studies (21). The search strategy included core search terms relating to influenza and corticosteroids (Supplementary Table 1).

In a three-stage screening process two authors independently assessed the titles, abstracts and full-text of retrieved articles for potential inclusion. Data extraction was done independently by two authors with arbitration by a third author as required. The risk of bias was evaluated at outcome level using the Cochrane Collaboration tool for RCTs and Newcastle-Ottawa Scale (NOS) for observational studies (22, 23). Overall quality of the evidence for the main outcomes of interest was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework (24).

Data Analysis

Dichotomous outcome data from individual studies were extracted as tabulated data from which risk ratios (RRs) or odds ratios (ORs) with 95% CIs were estimated. We extracted adjusted outcome measures as ORs or hazard ratios (HRs) with 95% CIs and presented these separately in pooled analyses. Where appropriate we estimated the effect of corticosteroids by random effects meta-analyses of pooled crude and adjusted ORs and pooled adjusted HRs for each outcome measure compared to no corticosteroids using the generic inverse variance method using Review Manager [Computer program], Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Heterogeneity was assessed using the I² statistic. Publication bias was assessed using funnel plots for meta-analyses containing ten or more studies.
To explore the putative interaction between corticosteroid dose and the magnitude of effect, we performed a meta-regression analysis using post-admission mortality as the dependent variable, and dose of corticosteroids as predictors. We performed random effects meta-regression analyses using the metareg command in Stata version 15.1 (Stata Corp, College Station, Texas).

Results

Study characteristics

We identified 3686 articles; of the 30 articles meeting the inclusion criteria, 21 were included in the meta-analysis of mortality (15, 25-44) and nine were included in the narrative synthesis only (45-53)(Figure 1). There was one RCT and the remainder were observational studies (99,224 individuals). The characteristics of included studies are summarised in supplementary table 2.

The median age of the cohort or corticosteroid-treated groups ranged from 2.5 to 63 years. One study included children only (31), the others included either adults only or people of mixed ages but predominantly adults. Disease severity at baseline was recorded in nine studies (15, 28, 30, 34, 36-38, 42, 49), five of which recorded higher baseline disease severity in the corticosteroid- treated group compared to the untreated group (30, 34, 36-38). Ten studies included only patients admitted to ICU (15, 27, 28, 30, 36-38, 40, 41, 44), with the remaining studies having mixed data for both ICU–admitted and non-ICU hospitalised patients.

Thirteen studies reported the doses or regimens of administered corticosteroids, with median/mean doses ranging from 40 to 141mg/day of methylprednisolone equivalent in ten studies (15, 26, 28, 30, 34, 36, 38, 39, 43, 52), and regimens of 1-6 mg/kg/day in three studies (35, 37, 51). Median duration of corticosteroid therapy in seven studies ranged from 5.1 to 11.0 days.
The risk of bias assessments for 46 reported outcomes from 30 observational studies and the one RCT are summarised in supplementary table 3 and supplementary figure 1. For the RCT (52), the methods of randomisation, allocation concealment and blinding were judged to be adequate. The maximum number of stars for the selection, comparability and outcome domains was achieved in 28, 14 and 36 of the 46 outcomes respectively. A high degree of correlation between corticosteroid treatment and potential confounders such as disease severity and co-morbid conditions was noted in several studies (28, 30, 34, 36, 42).

Effect on mortality

The nineteen studies of influenza A(H1N1)pdm09 conducted solely during the 2009 pandemic (15, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39, 40, 42-44, 46, 48, 49, 51), and five studies of seasonal/mixed seasonal and pandemic strains of influenza (29, 32, 38, 41, 52) reported either no difference or greater mortality associated with corticosteroid therapy. The single study of influenza A(H5N1) found an association between corticosteroid use and increased mortality after adjusting for neutropenia as a marker of disease severity (35). A study of influenza A(H7N9) reported no overall association with 30-day mortality although on subgroup analysis increased mortality and prolonged viral shedding were associated with high doses of corticosteroids (>150mg/day methylprednisolone equivalent) compared to no corticosteroids (26).

Reported timing of mortality from admission was inconsistent so stratification by 30-day mortality was not possible. Meta-analysis of 15 studies (2212 participants) showed significantly greater odds of mortality with corticosteroid use with moderate statistical heterogeneity (OR 3.90, 95% CI 2.31 to 6.60, $I^2$=68%)(Supplementary figure 2). On subgroup analysis both unadjusted and adjusted OR estimates showed an association between corticosteroid treatment and mortality (unadjusted OR 4.69, 95% CI 2.35 to 9.79, $I^2$=67%; adjusted OR 2.23, 95% CI 1.54 to 3.24, $I^2$=0%). An association with corticosteroid use was also found when the results of six studies
reporting adjusted HRs (aHR) were pooled (aHR 1.49, 95% CI 1.09 to 2.02, I²=68%)(Supplementary figure 3).

Increased risk of mortality in people treated with corticosteroids was observed in subgroup analysis of the ten studies that only included ICU-admitted critically-ill patients (OR 2.43, 95% CI 1.72 to 3.43, I²=0%, 7 studies, n=1295; adjusted HR 1.70, 95% CI 1.14 to 2.54, I²=60%, 3 studies, n=2246)(Figures 2a and 2b). The risk was also raised in the subgroup containing eight studies reporting ORs that had a mixed ICU/non-ICU population (OR 4.72, 95% CI 2.07 to 10.77, I²= 70%), although for the three studies reporting aHR, the risk was not significantly increased (aHR 1.31, 95% CI 0.73 to 2.35, I²=69%). Three studies analysed patients with acute respiratory distress syndrome (ARDS) separately, with pooled analysis indicating increased risk of death in the group treated with corticosteroids (OR 2.32, 95% CI 1.36 to 3.95, I²= 0%, n=392)(15, 30, 36). Pooled data for people who did not have ARDS from two of these studies showed a non-significant trend towards increased mortality risk with corticosteroid treatment (OR 2.54, 95% CI 0.77 to 8.39), with no significant subgroup difference between those with ARDS and no ARDS (p=0.89)(supplementary figure 4) A subgroup analysis of patients who were in shock versus those not in shock on admission to ICU was conducted in one study (38), with increased mortality risk associated with corticosteroid treatment in both groups (OR 1.60, 95% CI 1.21 to 2.13 and OR 1.89, 95% CI 1.22 to 2.95 respectively), with no significant difference between the subgroups (p=0.53).

The potential effect of corticosteroids at baseline for the treatment of pre-existing underlying conditions was considered in five studies, and patients were either excluded at the outset if they were receiving corticosteroids for chronic conditions (15, 28, 38) or a separate analysis was done of people who had not received prior corticosteroids (30, 32). Pooled analysis of data from only these patients showed a significant association between adjunctive corticosteroid treatment and risk of mortality (OR 2.01, 95% CI 1.39 to 2.90, I²=0%, 3 studies; aHR 1.78, 95% CI 1.29 to 2.45, I²=0%, 2 studies).
Funnel plot analysis did not reveal clear evidence of publication bias in the 21 studies included in the meta-analyses (Supplementary figure 5). We graded the certainty of the evidence specific to mortality as very low (supplementary table 4).

Three studies categorised corticosteroid dose as low or low/moderate and high. One study comparing low-dose (defined as <80 mg/day methylprednisolone equivalent) with higher corticosteroid doses found no difference in mortality risk ($p=0.854$) (43). A second study (288 participants) reported that compared to controls, patients receiving high-dose corticosteroids (>150 mg/day methylprednisolone equivalent) had increased mortality (HR 3.05, 95% CI 1.28 to 7.25, $p=0.012$), whereas in those treated with low to moderate dose corticosteroids the risk was not significantly different (HR 1.64, 95% CI 0.79 to 3.39, $p=0.183$) (26). In the third study (34), a large cohort of 2141 people, no overall effect of corticosteroids on mortality was found (HR 0.80, 95% CI 0.56 to 1.15), although when patients were stratified according to their disease severity as measured by their hypoxic status, low-moderate dose corticosteroids (25-150 mg/day methylprednisolone equivalent) were associated with decreased mortality in hypoxic people ($\text{PaO}_2/\text{FiO}_2 <300\text{mm/Hg}$), whereas high-dose corticosteroids had no beneficial effect in this group (HR 0.49, 95% CI 0.32 to 0.77, $p=0.02$ and HR 0.88, 95% CI 0.56 to 1.39, $p=0.58$ respectively). Neither low-moderate dose nor high-dose corticosteroids had a significant effect on 30-day mortality in non-hypoxic people.

Ten studies with data on corticosteroid dose were included in a random-effects meta-regression analysis (15, 26, 28, 30, 34, 36, 38, 39, 43, 52). Median daily dose was reported in seven of the studies, two reported total daily dose and one reported mean daily dose only. No significant interaction was observed between daily corticosteroid dose and mortality risk (regression co-efficient -0.0032; $p=0.745$) (Figure 3).

ICU Admission, Mechanical Ventilation, Length of Stay and Hospital-Acquired Infection

Studies reporting these outcomes are summarised in Table 1.
Seven studies presented data on the association between corticosteroid use and hospital-acquired infections. The definition of hospital-acquired infection varied but most studies reporting this outcome broadly defined it as the positive culture of a new pathogen (bacterial or fungal) from lower respiratory tract or blood cultures ≥48 hours after admission, and did not report results for different potential sources of infection separately. On pooled analysis, the overall risk of non-specific hospital-acquired infection was increased in patients treated with corticosteroids (OR 2.74, 95% CI 1.51 to 4.95, n=12,114)(supplementary figure 6), although all included estimates were unadjusted for potential confounders and statistical heterogeneity was high ($I^2=90\%$). Subgroup analysis of three studies which included only ICU-admitted patients showed a trend towards increased risk of infection in corticosteroid treated patients, but was not statistically significant (OR 2.10, 95% CI 0.98 to 4.52, $I^2=86\%$, n=1028, p=0.06).

Two ICU-based studies reported ventilator-associated pneumonia (VAP) separately (15, 38). Pooled analysis of unadjusted data suggested a non-significant trend toward increased risk of VAP with corticosteroids (OR 1.44, 95% CI 0.91 to 2.27, $I^2=44\%$, n=2054, p=0.12).

For hospital-acquired infection we graded the certainty of the evidence as very low (supplementary table 4).

**Discussion**

Our updated systematic review and meta-analysis is, to our knowledge, the most comprehensive analysis to date to investigate the effect of corticosteroids on clinical outcomes in people with confirmed influenza. The majority of the data are from observational studies and although we included one eligible RCT, it was not powered for mortality and had only a very small number of participants with confirmed influenza. Our main finding is that analysis of observational data suggests an association between corticosteroid treatment and increased risk of mortality.
Overall the quality of the evidence is very low and there are important considerations to take into account when interpreting the findings. Firstly, many of the included studies did not specify the indications for corticosteroid therapy. Some studies stated the rationale for giving corticosteroids therapy as adult respiratory distress syndrome (ARDS) and septic shock (15, 30, 43) and it is possible at one extreme that corticosteroids were only given to the sickest patients or those with refractory illness as a final attempt to treat. This is suggested from our subgroup analysis of studies that had separate data for ARDS and non-ARDS patients in which the mortality risk was only significantly elevated in the ARDS subgroup. No significant difference was noted between people who were shocked on admission to ICU and those who were not, although data were very limited with only one included study having separate data for shock. Conversely, corticosteroids may have been used to treat less severe comorbid diseases such as exacerbations of asthma, and although some of the included studies excluded patients who may have received prior corticosteroids for pre-existing conditions, or conducted a separate analysis of such patients, most did not.

A further important consideration relates to the dose of corticosteroid used. In our meta-regression we found no clear evidence of an association between the overall dose of corticosteroid and the risk of mortality. However, dose and duration of corticosteroids were poorly specified in many of the studies, and where reported, median doses were generally considerably higher than the dose typically recommended for the treatment of septic shock or exacerbations of airways disease such as asthma (54-56). Variability in corticosteroid dose and administration schedule are both factors that have been associated with treatment outcomes in the setting of severe sepsis; in particular high doses given in short bursts have not been associated with benefit compared to low doses given for longer duration (≥ 5 days)(57). A recent subgroup analysis of RCTS in sepsis did not find any credible effect modification with corticosteroid dose, although most of the evidence was from studies using hydrocortisone with or without fludrocortisone at low dose (<400 mg/d hydrocortisone or equivalent) and over a long
duration (>2 days)(10). RCTs of corticosteroids in CAP have typically used much lower doses (32mg-40mg methylprednisolone equivalent) (12) than we noted in our included studies. Data from studies using low-dose steroids (≤40 mg/day MP equivalent) were lacking in our review. As the doses in our review were typically high, we cannot exclude the possibility that low-dose corticosteroids may have a different effect on mortality, or that there may be particular patient subgroups in whom their use may indeed be of benefit, as suggested by some of the individual included studies (26, 34). The use of higher doses of corticosteroids may also explain the greater risk from hospital-acquired infections which we noted. Corticosteroid use has been reported to be an independent risk factor for the development of invasive fungal infections in adults admitted to ICUs with influenza (58). Additionally, there is weak evidence from a recent observational study that influenza infection and corticosteroid treatment are both independent risk factors for the development of invasive pulmonary aspergillosis which is itself associated with high mortality (59).

The evidence base from clinical trials of corticosteroids in the setting of sepsis and pneumonia contrast with the findings from our review. Specifically, recent meta-analysis of prolonged low-dose corticosteroids in sepsis (which included two recent large RCTs, the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial (60) and the Adjunctive Glucocorticoid Therapy in Patients with Septic Shock (ADRENAL) trial (61)) concluded that corticosteroids may achieve a small reduction or no reduction in the risk of dying in the short-term with a possible small decrease in longer-term mortality (60 days to 1 year)(10). Thus there is strong evidence from RCTS that corticosteroids in sepsis do not have a large positive effect. In the setting of CAP (not specifically influenza), an association between corticosteroid therapy and decreased mortality, need for mechanical ventilation and hospital length of stay has been shown (62). Other systematic reviews have also demonstrated a beneficial effect of corticosteroids on mortality and other clinical outcomes, but only in people with severe CAP (12, 63-66). Subgroup analyses by individual aetiological pathogens were not
possible in these systematic reviews due to lack of separation of outcome data by pathogen or lack of microbiological confirmation in the included studies. Large trials of corticosteroids in severe pneumonia are currently underway and should provide more robust data in the next few years (67, 68).

Limitations of our review include the current lack of evidence from relevant RCTs. Although we did not restrict our inclusion criteria to particular patient demographics, study settings or influenza subtype, we identified only one RCT which was not directly relevant to our review question. There was a high correlation between corticosteroid therapy and potential confounders for measured outcomes, such as disease severity and comorbid illnesses, so confounding by indication is likely to be a significant bias in studies which only provided unadjusted effect estimates. Additionally, time to hospitalization, antiviral use, presence of respiratory failure prior to corticosteroids, and the rationale for corticosteroid use were sparsely reported across studies. Clinical heterogeneity between the studies was also apparent in the measurement of disease severity with a range of clinical risk scores used, reported timing of mortality, types and doses of corticosteroids, and the consistency of use of co-interventions such as antivirals and antibiotics. Our meta-regression analysis of corticosteroid dose was limited by the lack of studies with data for low-dose corticosteroids, and there was also variation of doses used within the included studies. However, we believe that it is valuable in that it highlights an important gap in the evidence, and particularly so in light of meta-analyses of corticosteroids in sepsis and CAP, where low-dose steroids may have some beneficial clinical effects.

Conclusions

This systematic review highlights that the current evidence base is still not strong enough to make firm recommendations regarding the effectiveness or otherwise of corticosteroids as adjunctive treatment in people with proven influenza. Discrepancies remain between the findings in influenza and other clinical situations, but there are
important differences in terms of study designs and doses of corticosteroids used. The question of whether low doses of corticosteroids may be of some benefit in particular subgroups of patients with influenza requires further study and there is a clear need for well-designed RCTs to examine the effects of corticosteroids on clinical outcomes, particularly addressing the effects of low-dose corticosteroids and to include severely ill patients with influenza complications including primary viral pneumonia, septic shock and ARDS. This supports the updated World Health Organization Research Agenda recommendations for optimising the treatment of patients with influenza (69). In the meantime our results continue to support existing WHO recommendations (70) that systemic corticosteroids should be avoided in influenza patients unless indicated for other reasons or as part of an approved research protocol. In the current absence of finer details regarding the risks associated with subcategories of critically-ill influenza patients, and given the concerns regarding invasive secondary infections, caution should at the very least be applied before offering corticosteroids to anyone with severe influenza and it is not advisable to routinely give them to such patients.

Acknowledgements

We would like to express our gratitude to Vadsala Baskaran, Sara Belazi, Hannah Lawrence and Harry Pick for their help with data extraction. We also thank Liz Dooley, Ann Jones and other members of the Cochrane Acute Respiratory Infections Group for their help and editorial advice during the preparation of this systematic review.
References

1. McClain MT, Henao R, Williams J, et al. Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge. *Clin Exp Immunol* 2016;183(3):441-51
2. Lee N, Wong CK, Chan PK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. *PLoS One* 2011;6(10):e26050
3. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. *PloS One* 2011;6(12):e28680
4. Heltzer ML, Coffin SE, Maurer K, et al. Immune dysregulation in severe influenza. *J Leukoc Biol* 2009;85(6):1036-43
5. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. *Nat Rev Immunol* 2017;17(4):233-47
6. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol* 2011;335(1):2-13
7. Kaufmann, Briegel J, Schliephake F, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. *Intensive Care Med* 2008;34(2):344-9
8. Annane D, Pastores SM, Arlt W, et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). *Intensive Care Med* 2017;43(12):1781-92
9. Marik PE. Critical illness-related corticosteroid insufficiency. *Chest* 2009;135(1):181-93
10. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med 2018;46(9):1411-20
11. Lamontagne F, Rochwerg B, Lytvyn L, et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ 2018. p. k3284-k
12. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017(12)
13. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009;302(17):1872-9
14. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013;207(4):553-63
15. Brun-Buisson C, Jean-Christophe M, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011;183(9):1200-6
16. Diaz E, Martin-Loeches I, Canadell L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012;64(3):311-8
17. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2016(3)
18. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
19. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008-12
20. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 510 [updated March 2011] The Cochrane Collaboration, 2011 Available at: https://handbook-5-1.cochrane.org Accessed January 22, 2019
21. Scottish Intercollegiate Guidelines N. Search filters, observational studies. Available at: https://www.sign.ac.uk/search-filters.html Accessed January 21, 2019

22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: https://handbook-5-1.cochrane.org Accessed January 21, 2019

23. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed January 21, 2019

24. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime); 2015 Available at: https://gdtGRADEpro.org/app Accessed January 21, 2019

25. Balaganesakumar SR, Murhekar MV, Swamy KK, et al. Risk factors associated with death among influenza A (H1N1) patients, Tamil Nadu, India, 2010. J Postgrad Med 2013;59(1):9-14

26. Cao B, Gao H, Zhou BP, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med 2016;44(6):e318-28

27. Chawla R, Kansal S, Chauhan M, et al. Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): experiences of a tertiary care center. Indian J Crit Care Med 2013;17(5):275-82

28. Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care 2016;20(75)

29. Huang SF, Fung CP, Perng DW, et al. Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus. J Microbiol Immunol Infect 2017;50(5):586-94

30. Kim S, Hong S, Yun S, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011;183(9):1207-14
31. Kinikar AA, Kulkarni RK, Valvi CT, et al. Predictors of mortality in hospitalized children with pandemic H1N1 influenza 2009 in Pune, India. *Indian J Pediatr* 2012;79(4):459-66
32. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. *Eur Respir J* 2015;45(6):1642-52
33. Li F, Chen G, Wang J, et al. A case-control study on risk factors associated with death in pregnant women with severe pandemic H1N1 infection. *BMJ Open* 2012;2(4):e000827-e
34. Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. *Influenza Other Respir Viruses* 2017;11(4):345-54
35. Liem N, Tung C, Hien N, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. *Clin Infect Dis* 2009;48(12):1639-46
36. Linko R, Pettila V, Ruokonen E, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A (H1N1) infection in Finland. *Acta Anaesthesiol Scand* 2011;55(8):971-9
37. Mady A, Ramadan O, Yousef A, et al. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. *J Infect Public Health* 2012;5(1):52-6
38. Moreno G, Rodriguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. *Intensive Care Med* 2018;44(9):1470-82
39. Patel K, Patel A, Mehta P, et al. Clinical outcome of novel H1N1 (swine flu)-infected patients during 2009 pandemic at tertiary referral hospital in western India. *J Glob Infect Dis* 2013;5(3):93-7
40. Sertogullarindan B, Ozbay B, Gunini H, et al. Clinical and prognostic features of patients with pandemic 2009 influenza a (H1N1) virus in the intensive care unit. *Afr Health Sci* 2011;11(2):163-70
41. Sheu CC, Chang WA, Tsai MJ, et al. Early corticosteroid treatment in patients with influenza-associated acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2017;195(Abstract Issue)

42. Viasus D, Pano-Pardo J, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. *J Infect* 2011;62(3):193-9

43. Xi X, Xu Y, Jiang L, et al. Hospitalized adult patients with 2009 influenza A (H1N1) in Beijing, China: risk factors for hospital mortality. *BMC Infect Dis* 2010;10:256-

44. Yu Ht, Yang Yj, Zhang Qx, et al. Clinical characteristics and risk factors of severe patients with novel pandemic influenza A H1N1. *Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care* 2011;18(3):142-5

45. Al-Busaidi M, Al Maamari K, Al'Adawi B, et al. Pandemic influenza a H1N1 in Oman: Epidemiology, clinical features, and outcome of patients admitted to Sultan Qaboos University Hospital in 2009. *Oman Med J* 2016;31(4):290-7

46. Delgado-Rodriguez M, Castilla J, Godoy P, et al. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. *J Antimicrob Chemother* 2012;67(7):1739-45

47. Boudreault A, Xie H, Leisenring W, et al. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. *Biol Blood Marrow Transplant* 2011;17(7):979-86

48. Jain S, Kamimoto L, Bramley A, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. *N Engl J Med* 2009;361(20):1935-44

49. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. *Clin Infect Dis* 2011;53(4):326-33

50. Ono S, Ono Y, Matsui H, et al. Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort. *BMC Public Health* 2016;16:.922-

51. Kudo K, Takasaki J, Manabe T, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A (H1N1) pdm09 in Japan. *PloS One* 2012;7(2):e32280
52. Wirz SA, Blum CA, Schuetz P, et al. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. *Eur Respir J* 2016;48(4):1150-9

53. Wu U, Wang J, Ho Y, et al. Factors associated with development of complications among adults with influenza: a 3-year prospective analysis. *J Formos Med Assoc* 2012;111(7):364-9

54. British Thoracic Society/Scottish Intercollegiate Guidelines Network. BTS/SIGN British guideline for the management of asthma, 2016, SIGN 153. Available at: https://www.sign.ac.uk/sign-153-british-guideline-on-the-management-of-asthma.html Accessed January 21, 2019

55. National Clinical Guideline Centre. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available at: https://www.nice.org.uk/guidance/NG115 Accessed January 21, 2019

56. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med* 2017;43(3):304-77

57. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating sepsis. *Cochrane Database Syst Rev* 2015(12)

58. Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. *Intensive Care Med* 2012;38(11):1761-8

59. Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet Respir Med* 2018;6(10):782-92

60. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med* 2018;378(9):809-18

61. Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med* 2018;378(9):797-808
62. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. *Ann Intern Med* 2015;163(7):519-28

63. Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. *PLoS ONE* 2016;11(11):e0165942

64. Horita N, Otsuka T, Haranaga S, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. *Sci Rep* 2015;5:14061

65. Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. *PLoS ONE* 2015;10(12):e0144032

66. Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. *Am J Emerg Med* 2018;36(2):179-84

67. NCT01743755 Santeon-CAP; Dexamethasone in community-acquired pneumonia. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01743755?term=SANTEON&rank=1

Accessed January 21, 2019

68. NCT2517489 Community-acquired pneumonia : evaluation of corticosteroids. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02517489?term=CAPE+COD&rank=3

Accessed January 21, 2019

69. WHO public health research agenda for influenza: 2017 update. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO

70. World Health Organisation (WHO). WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. 2010. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf
Figure Legends

**Figure 1** Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) flow diagram for the article selection process

**Figure 2a and 2b** Meta-analysis of studies reporting mortality stratified by ICU admission status.

- Figure 2a Odds Ratios (ORs)
- Figure 2b Hazard Ratios (HRs)

Footnote for figure 2: Mortality estimates determined using random effects modelling.

CI Confidence intervals; CS Corticosteroids; HR Hazard Ratio; OR Odds Ratio; SE Standard Error

**Figure 3** Random-effects meta-regression of log of mortality effect size and dose of corticosteroid expressed as methylprednisolone equivalent per day.

Footnote for figure 3: Estimates from each included study are represented as circles. The area of each circle is inversely proportional to the variance of the log effect size, with circle area representative of the weight of each study.

Tables

**Table 1** Summary of studies reporting clinical outcomes other than mortality
Supplementary Digital Content legends

**Supplementary Table 1** Search Strategy for MEDLINE (OVID)

**Supplementary Table 2** Characteristics of Included Studies

**Supplementary Table 3** Risk of Bias in observational studies using the Newcastle-Ottawa Scale

**Supplementary Table 4** GRADE assessment of outcomes

**Supplementary Figure 1** Risk of Bias of included Randomised Controlled Trial

**Supplementary Figure 2** Meta-analysis of studies reporting mortality: Odds ratios (ORs)

**Supplementary Figure 3** Meta-analysis of studies reporting mortality: Hazard ratios (HR)

**Supplementary Figure 4** Subgroup analysis of studies reporting patients with ARDS versus no ARDS

**Supplementary Figure 5** Funnel plot analysis for publication bias for 21 studies included in mortality meta-analyses

**Supplementary Figure 6** Meta-analysis of studies reporting hospital-acquired infections